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The aim of cancer immunotherapy is to treat malignant disease by inducing or enhancing
cancer specific immune responses. With the identification of tumor-associated antigens
(TAAs†) in the 1990s, cancer immunotherapy research largely focused on inducing immune
responses against TAAs but achieved limited success. More recently, the underlying mech-
anisms and molecular pathways that cancers manipulate to subvert immune-mediated de-
struction have been identified, including a set of molecules with potent coinhibitory functions.
Coinhibitory molecules are expressed on the surface of immune cells, cancer cells, and
stromal cells and negatively regulate immune responses to cancer. In particular, one of
these ligand-receptor coinhibitory interactions, B7-H1/PD-1, is critical for modulating im-
mune responses to cancer. This knowledge led to the design of revolutionary new im-
munotherapeutics based on the manipulation of these molecular pathways. Monoclonal
antibodies (mAbs) are the primary immunotherapeutic modality used to promote immune
function via antagonism or agonism of inhibitory or stimulatory molecular pathways, re-
spectively. Here, we review current knowledge on the function of the B7-H1/PD-1 pathway
in mice and humans, its role in the subversion of immune responses in cancer, and clinical
evidence that mAb targeting of this pathway results in profound immune anti-cancer effects.
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†Abbreviations: PD-1, programmed death-1; B7-H1, B7-homolog-1; CSSMs, cell surface
signaling molecules; TCR, T cell receptor; MHC, major histocompatibility complex; APC,
antigen presenting cell; CTLA-4, cytotoxic T lymphocyte antigen-4; BTLA, B and T lym-
phocyte attenuator; Tim-3, T cell immunoglobulin and mucin domain-3; Lag-3, lymphocyte
activation gene-3; TNF, tumor necrosis factor; IFN, interferon; TILs, tumor infiltrating lym-
phocytes; GVHD, graft versus host disease; ITIM, immunoreceptor tyrosine-based in-
hibitory motif; ITSM, immunoreceptor tyrosine-based switch motif; BATF, basic leucine
zipper transcription factor of the ATF family; PTEN, Phosphatase and Tensin Homology;
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In  The  Selfish  Gene by  Richard
Dawkins, the question is posed: “What makes
a good gene?” Dawkins proposes that a good
gene, from an evolutionary perspective, is de-
fined by longevity, fecundity, and copying-fi-
delity [1]. He goes further to suggest that a
good gene must also be good at making “sur-
vival machines,” or in other words, enhance
the survival and reproductive capacity of an
organism. However, as the incidence of can-
cer increases in the industrial era, perhaps due
to lengthening human life spans, industrial
and occupational risks, environmental fac-
tors, and other causes, we face the realization
that humans have not evolved to deal effec-
tively with cancer [2,3]. Many cases of can-
cer occur after the reproductive age, limiting
the ability of evolutionary processes to select
for good anti-cancer genes [2,3].
The evolutionary selection of good anti-
cancer genes is particularly interesting with
respect to the immune response to cancer.
Some components of immunity critical for
human survival, ironically, also may be ex-
ploited for the survival and progression of
cancer [4,5]. With this in mind, we can hardly
describe such immune components as dys-
functional, as they are performing precisely
as evolutionary design dictates. In fact, some
negative regulatory components of the im-
mune system may have enhanced function in
the cancer microenvironment, thus promot-
ing cancer progression rather than halting it
[4,5]. These genes may act as double-edged
swords in the cancer microenvironment to
dampen inflammatory responses while si-
multaneously preventing optimal immune de-
struction of transformed cells.
Costimulatory and coinhibitory mole-
cules that represent a subgroup of cell sur-
face  signaling  molecules  (CSSMs)  are
particularly susceptible to manipulation by
cancers [6,7]. CSSMs provide cells of the
immune system with decision-making input
following initial triggering by a primary sig-
nal [6,7]. In T cells, the primary signal is
generated in an immunological synapse via
T  cell  receptor  (TCR)  engagement  of  a
major histocompatibility complex molecule
(MHC), which presents antigenic peptide on
the surface of an antigen presenting cell
(APC) (reviewed in [8]). Cosignaling occurs
via T cell cosignaling receptor molecules
binding to ligand molecules expressed on
APCs. These interactions further enhance or
dampen primary signaling pathways [8]. Co-
signals are involved in all phases of T cell
function including priming, activation, ex-
pansion, effector function, and contraction
[9,10]. Several families of cosignaling mol-
ecules have now been identified and charac-
terized  as  functional  modulators  of  T
cell-mediated immune responses [9,10].  
CD28  and  B7  family  molecules  are
considered  the  best-characterized  sets  of
cosignaling molecules. These families in-
clude both costimulatory and coinhibitory
receptors and ligands with CD28-like mole-
cules primarily interacting with molecules
of the B7 family [6,7]. The interactions be-
tween CD28 and B7 family molecules are
critical for immune responses to infection
and disease [6,7]. T cell activation, for ex-
ample, depends on the binding of CD28 to
B7-1 (CD80) and B7-2 (CD86) on APCs,
while Cytotoxic T-Lymphocyte Antigen-4
(CTLA-4; CD152), another member of the
CD28 family, down-regulates T-cell activity
when it engages B7-1 and B7-2 [6,7]. A re-
cent study shows that B7-H2 (CD275), a B7
family molecule best known as the ligand
for Inducible Costimulator (ICOS), is the
third ligand for CD28 and CTLA-4 in hu-
mans  [11].  The  complete  set  of  known
CD28 and B7 family members and their in-
teractions are reviewed elsewhere [12-15].
Molecules of the B7-H1/PD-1 pathway
are  critical  modulators  of  immune  re-
sponses.  Programmed  Death-1  (PD-1;
CD279) is a member of the CD28 family ex-
pressed on activated T cells, B cells, den-
dritic  cells,  and  macrophages  [12-15].
Engagement of PD-1 inhibits function in
these immune cell subsets [6,16]. PD-1 has
two known counter-receptors or ligands, B7-
H1 (CD274, PD-L1) and B7-DC (CD273,
PD-L2) of the B7 family. While B7-H1 ex-
pression is inducible on a variety of cell
types in lymphoid and peripheral tissues,
B7-DC is more restricted to myeloid cells,
including dendritic cells [12-15]. The B7-
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pivotal role in the negative regulation of T
cell activity, including suppression of im-
mune responses against cancer [6,7].
While the major role of the B7-H1/PD-
1 pathway is to tune down inflammatory im-
mune responses in tissues and organs, this
function is manipulated by cancer as a way to
escape from immune destruction. In this re-
view, we illustrate these mechanisms and de-
scribe  how  interventions  utilizing  mAb
immunotherapy to block this molecular path-
way may re-awaken the immune system to
engender a dramatic counter-attack against
cancers. Using these methods, we may re-
verse a mechanism by which cancers manip-
ulate otherwise good genes.
overvIew oF tHe PD-1/B7-H1/B7-
DC PAtHwAy
Regulatory  elements  of  the  immune
system exist primarily to prevent the dam-
aging immunopathology that accompanies
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Figure 1. B7-H1/PD-1 mAb blockade reverses t cell suppressor and tumor protec-
tive mechanisms. In tumor microenvironments, engagement of PD-1, expressed on
CD8+ T cells, with B7-H1, expressed on tumor cells, results in T cell suppression and
tumor protection. PD-1 signaling in T cells following engagement of B7-H1 inhibits T cell
function resulting in an exhausted phenotype characterized by decreased expression of
effector molecules and ultimately may result in T cell deletion. B7-H1 expressed on tumor
cells induces anti-apoptotic survival factors in tumor cells following engagement of PD-1
on T cells, while the role of B7-DC in the tumor microenvironment remains unclear at this
time. Meanwhile, tumor associated B7-H1 and B7-1 molecules interacting with B7-1 and
B7-H1 on T cells, respectively, induce non-functional anergic T cells. Blockade of PD-1 in-
teraction with B7-H1 using anti-PD-1 mAbs can reverse the exhausted phenotype of CD8+
T cells and permits subsequent CD8+ T cells responses against tumor antigens. Blockade
of B7-H1 using anti-B7-H1 mAbs reverses CD8+ T cell exhaustion, blocks tumor cell mo-
lecular shielding mechanisms and may prevent the inhibitory interactions between B7-H1
and B7-1.excessive  responses  against  infection,  as
well as to block autoimmune responses by
maintaining peripheral tolerance of self-anti-
gens. The B7-H1/PD-1 molecular cosignal-
ing axis appears to play a critical role in both
of these processes. This premise has been
substantiated by analysis of mice that are ge-
netically deficient in various components of
this axis [17-20]. Experimental mouse mod-
els in which signaling through these path-
ways  are  blocked  by  mAbs,  including
alloantigen  and  graft-versus-host-disease
(GVHD) models, autoimmune disease mod-
els,  and  fetomaternal  tolerance  models,
demonstrate  that  this  pathway  generally
functions to prevent excessive peripheral
immune  responses  and  associated  im-
munopathology [21,22].
PD-1 is a Coinhibitory Receptor 
Expressed on Activated T Cells 
PD-1 and coinhibitory receptors such as
CTLA-4, B and T Lymphocyte Attenuator
(BTLA; CD272), T cell Immunoglobulin
and Mucin domain-3 (Tim-3), Lymphocyte
Activation Gene-3 (Lag-3; CD223), and oth-
ers are often referred to as a checkpoint mol-
ecules or, more appropriately, checkpoint
CSSMs [6,7]. They act as molecular “toll-
booths,” which allow extracellular informa-
tion to dictate whether cell cycle progression
and other intracellular signaling processes
should proceed [23]. Ample evidence shows
that  PD-1  is  a  coinhibitory  receptor  ex-
pressed on activated T cells that negatively
regulates T cell function. For example, a
high level of PD-1 expression on antigen-
experienced CD8+ T cells is associated with
a CD8+ T cell phenotype termed “T cell ex-
haustion.” This phenotype is defined by im-
paired effector function and the persistent
expression of inhibitory receptors (reviewed
in [24]). Exhausted CD8+ T cells gradually
lose effector functions, including the capac-
ity to proliferate, the ability to express cy-
tokines  like  Interleukin-2  (IL-2),  Tumor
Necrosis Factor-α (TNF-α), and Interferon-
γ (IFN-γ), the expression of effector mole-
cules like perforin, and eventually appear to
undergo apoptosis [24]. Exhausted PD-1-ex-
pressing CD8+ T cells have been identified
among  tumor-infiltrating  lymphocytes
(TILs) in cancers, as well as in chronic viral
infections  (Figure  1)  [24].  However,  the
exact mechanism by which PD-1 expression
inhibits CD8+ T cell function is not com-
pletely understood.
B7-H1 is the major ligand for PD-1
mediated immunosuppression. It is consti-
tutively  expressed  on APCs  and  can  be
broadly induced on cells in both lymphoid
tissues and non-lymphoid peripheral tissues
following cellular activation, making B7-
H1 ideally suited for peripheral modulation
of activated T cells [18,21,25]. The cytokine
IFN-γ is particularly effective in upregulat-
ing B7-H1 due to IFN-γ response elements
in the B7-H1 promoter region [12-15]. The
expression of B7-DC, another ligand of PD-
1, is largely restricted to myeloid DCs and
macrophages  in  lymphoid  compartments
and is not broadly expressed in peripheral
tissues or on multiple cell types, thus mak-
ing it less effective at dampening peripheral
T cell responses [12-15].
PD-1 engagement on T cells stimulated
with anti-CD3 and anti-CD28 mAbs deliv-
ers an inhibitory signal that blocks PI3K ac-
tivity and subsequent downstream activation
of Akt [26]. Although the cytoplasmic tail of
PD-1 contains both an immunoreceptor ty-
rosine-based inhibitory motif (ITIM) and an
immunoreceptor  tyrosine-based  switch
motif (ITSM), both of which can have in-
hibitory function, it was found by mutational
analysis that only the ITSM, and not the
ITIM motif, is required for the suppression
of PI3K/Akt activation and T cell expansion
[26]. PD-1 engagement recruits both SHP-1
and SHP-2, SH2-domain containing protein
tyrosine phosphatases, which dephosphory-
late and deactivate downstream signaling
components [26]. However, the role of SHP-
1/2 in PD-1 mediated inhibition remains un-
clear at this time, while the possibility exists
that other signaling molecules found to in-
teract with the PD-1 cytoplasmic tail may
play an important role in T cell inhibition. 
Studies of the regulation of PD-1 ex-
pression on CD8+ T cells, using an inte-
grated genomics approach, have identified a
number of associated signaling molecules.
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factor of the ATF family, may promote ex-
haustion following PD-1 ligation by nega-
tively  regulating  the  AP-1  transcription
factor by displacing c-Fos/c-Jun dimeriza-
tion [27-29]. Additionally, the transcription
factors Blimp-1 and NFATc1 are associated
with exhausted T cells, and both regulate
PD-1 expression. By contrast, the transcrip-
tion factor T-bet may repress PD-1 expres-
sion and promote sustained CD8+ T cells
responses [21,22]. Nevertheless, correlation
studies do not paint a clear picture of the true
relation of PD-1 expression and distal sig-
naling events on exhausted CD8+ T cells.  
Phenotypes of Mice Deficient in 
PD-1,B7-H1 and B7-DC 
Mouse strains deficient in components
of the PD-1 pathway display moderate, pro-
gressive autoreactive phenotypes, primarily
in peripheral tissues. PD-1 knockout (KO)
mice develop strain-dependent late-onset au-
toimmune-like pathologies (including lupus-
like  arthritis,  glomerulonephritis,  and
cardiomyopathy), while B7-H1 KO mice ac-
cumulate seemingly non-functional CD8+ T
cells in peripheral organs over time without
autoimmune manifestations, likely due to
lack of PD-1 dependent T cell apoptosis and
clearance [12-15]. Meanwhile, B7-DC defi-
cient mice display no obvious phenotype but
develop  enhanced  immunopathology  in
asthma models [30]. The phenotype of PD-
1/B7-H1/B7-DC KO mice is in contrast to
CTLA-4 KO mice, which display a much
more acute and systemic autoimmune phe-
notype [18,21,25]. However, mechanisms
have not been fully defined for the differ-
ences  in  autoimmune  toxicity  in  these
mouse strains.
Additional Mechanisms of T cell 
Regulation by the PD-1/B7-H1 
Molecular Axis
The identification of additional interac-
tions within this molecular axis expands po-
tential mechanisms of action and distorts
receptor/ligand designations. First, as dis-
cussed previously, not only does B7-H1 de-
liver a regulatory signal through PD-1, it has
been shown that PD-1 is capable of deliver-
ing a reverse signal through B7-H1 on can-
cer cells to induce an anti-apoptotic effect
[31]. Second, B7-H1 can engage B7-1 to de-
liver an inhibitory signal to T cells and in-
duce T cell suppression in vitro and T cell
tolerance in vivo [32,33]. Finally, evidence
suggests that additional receptors for B7-H1
and B7-DC exist through which these mol-
ecules deliver costimulatory signals [6,7].
These findings blur the lines between recep-
tor and ligand and between stimulatory and
inhibitory signaling within this molecular
axis. Therefore, although the primary func-
tion of this molecular axis is clearly nega-
tive modulation of effector T cell activity, it
will be critical to elucidate how this pathway
is involved in regulating immune responses
within specific environments.  
SuBverSIon oF tHe PD-1/B7-H1
PAtHwAy By CAnCerS
Although it was once unclear if tumor
immunosurveillance existed, we now be-
lieve the immune system constantly moni-
tors and eliminates newly transformed cells
[4,34]. Accordingly, cancer cells may alter
their phenotype in response to immune pres-
sure in order to escape attack [4,34]. This
“immunoediting” hypothesis largely deals
with the relationship between cancer cells
and the immune response during the early
stages of tumorigenesis. However, ample
evidence suggests subsequent progression of
primary tumors and metastases employs a
wide  variety  of  subversive  processes  to
maintain their own survival [4,5]. Subver-
sion of anti-tumor immunity is believed to
be a mechanism by which cancers maintain
unbridled growth and metastasis [4,5].
Numerous studies indicate that the can-
cer microenvironment manipulates the B7-
H1/PD-1  molecular  pathway  and  that
induction of B7-H1 expression is associated
with inhibition of immune responses against
cancer, thus permitting cancer progression
and metastasis [35,36]. The B7-H1/PD-1
molecular pathway is a primary mechanism
of cancer immune evasion for several rea-
sons. First, and most importantly, this path-
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mune responses, particularly in peripheral
tissues where cancers often originate and
grow. Second, B7-H1 is upregulated in can-
cer microenvironments, while PD-1 is also
upregulated on activated tumor infiltrating
T cells, thus possibly potentiating a vicious
cycle of inhibition. Third, this pathway is in-
tricately involved in both innate and adap-
tive  immune  regulation  through
bi-directional signaling. These factors make
the PD-1/B7-H1 molecular pathway a cen-
tral point through which cancer can manip-
ulate immune responses and promote its
own progression. In other words, manipula-
tion of the B7-H1/PD-1 molecular axis by
cancers results in “good genes” gone bad.   
Tumor Evasion via B7-H1 Expression
in the Cancer Microenvironment 
B7-H1 mRNA is found in virtually all
tissues and nucleated cells examined to date,
while B7-H1 protein expression appears lim-
ited [21,22]. Studies demonstrate that B7-H1
can be broadly induced on lymphoid and
non-lymphoid cells alike following stimula-
tion with type I (α, β) and type II (γ) IFNs
[37,38].  Numerous  studies  have  demon-
strated the presence of cell surface B7-H1 in
murine and human tumors, and expression of
B7-H1 has been linked to poor clinical out-
comes in a variety of cancers [16]. These re-
sults suggest that B7-H1 expression may be
a primary mechanism by which cancers sub-
vert immune responses by suppression of
PD-1-expressing CD8+ T cells.
B7-H1 is expressed on some murine
tumor cell lines, and mouse models have
confirmed that B7-H1 over-expression on
transplantable  tumors  impairs  anti-tumor
immunity.  Using  transplantable  and  sys-
temic tumor models including P815 masto-
cytoma, SCCVII squamous cell carcinoma,
B16 melanoma, C1498 AML, Panc02 pan-
creatic cancer, and others, it became evident
that  B7-H1  expression  significantly  en-
hances tumor growth and causes apoptosis
of tumor-specific T cells [35,36]. Mean-
while, mAb blockade of B7-H1 ligation to
PD-1 in these models permits cytotoxic ac-
tivity and reverses tumor growth.  
An analysis of human tumor cell lines
found that few have baseline expression of
B7-H1.  However,  immunohistochemical
analysis of freshly isolated tumor samples
from patients with ovarian, lung, and breast
cancers, renal cell carcinoma, squamous cell
carcinoma of the head and neck, esophageal
carcinoma, glioblastoma, thymoma, colon
carcinoma, and melanoma found that the
vast majority express B7-H1 [35,36]. In one
study, 22 out of 22 melanoma samples ex-
amined stained positively for B7-H1, with
the majority of samples showing expression
in at least 40 percent of cells [37,38]. Im-
portantly, these findings illustrate that B7-
H1 is widely expressed in cancer cell and
cancer microenvironments, yet expression
remains heterogenous [36]. The underlying
mechanism for the “compartmentalization”
of B7-H1 expression remains unclear.  
Cytokines such as IFN-γ in the tumor
environment are believed to be a main driver
of the expression of B7-H1, though the over-
all mechanism of B7-H1 upregulation is yet
to be elucidated. Most human and mouse
tumor cell lines examined are capable of
quickly upregulating B7-H1 following incu-
bation  with  IFN-γ [37,38].  Studies  of
glioblastoma cell lines have correlated in-
creased B7-H1 expression to the loss of the
tumor  suppressor  gene  Phosphatase  and
Tensin Homology (PTEN), a negative regu-
lator of the intracellular signaling molecule
PI3K [39]. Expression of B7-H1 has been
correlated with poor clinical outcomes, in-
cluding decreased survival, in a number of
human cancers, including esophageal, ovar-
ian, pancreatic, and renal cell carcinoma
(RCC)  [16].  For  example,  patients  with
RCC  tumors  expressing  B7-H1  were  at
greater risk of metastatic dissemination, and
their risk of death was nearly four times
greater than patients with B7-H1-negative
tumors [40]. These studies further support a
role for the B7-H1/PD-1 pathway in subver-
sion of tumor immunity and point to B7-H1
expression as a useful biomarker to identify
patients at greater risk of metastatic disease
progression  and  death.  Moreover,  this
knowledge  supports  the  development  of
therapies to block this pathway in order to
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against cancers.
MonoClonAl AntIBoDy 
IMMunotHerAPy tArgetIng 
PD-1 AnD B7-H1
Cancer immunotherapy is a rapidly de-
veloping field as immunologists continue to
elucidate how the immune system responds
to and is subverted by cancers. A variety of
immunotherapeutic modalities are currently
being developed, including mAbs and small
molecules. However, advantages of mAb
immunotherapy include target specificity
and affinity, persistence in vivo, and sec-
ondary function of mAbs through the crys-
talline  fragment  (Fc)  and  glycosylation
effects [41]. Additionally, engineering for
therapeutic optimization, increasing ease of
production, and reductions in cost of pro-
duction of mAbs have progressed rapidly in
the past 10 years, as reviewed in detail else-
where [42]. Mechanisms through which im-
munotherapeutic  mAbs  may  function
include antagonism (physical blockade), ag-
onism (signal induction through antibody
cross-linking  of  receptors),  antibody  de-
pendent cellular cytotoxicity (ADCC), com-
plement  dependent  cytotoxicity  (CDC),
toxin conjugation to Fc portions of mAb,
and bi-specific mAbs, which simultaneously
target two epitopes. These mechanisms are
reviewed in detail elsewhere [41].  
CSSMs make ideal targets for mAb im-
munotherapy because they are broadly ac-
cessible for mAb binding and typically have
very specific functions in immune modula-
tion. Antagonist mAbs targeting inhibitory
CSSMs such as PD-1 and B7-H1 promote
immune activation against cancer, which re-
sults in the generation of immune memory
and,  consequently,  a  durable  response
against cancer, which is of critical impor-
tance in immunotherapeutics [23]. By con-
trast,  small  molecule  inhibitors  targeting
intracellular  signaling  proteins  in  cancer
cells, blood vessels, or stromal components
(e.g., vemurafenib, an inhibitor of the ser-
ine-threonine kinase B-Raf, a protein found
mutated in some cancers) efficiently sup-
press growth or cause death of cancer cells
but often do not eliminate all cancer cells
due to acquired or innate resistance and do
not directly stimulate adaptive immune re-
sponses [43]. Thus, immune escape and can-
cer progression are likely without adaptive
immune memory generation.  
Lessons Learned from Murine Tumor
Models
As discussed previously, expression of
B7-H1 on human cancer cells and in cancer
microenvironments has been shown to cor-
relate with their growth and progression.
Several mouse models confirmed that B7-
H1 overexpression by transfection on trans-
plantable  tumors  impairs  anti-tumor
immunity,  while  blockade  of  B7-H1  by
mAb  enhanced  tumor  immunity  [35,36].
Moreover, growth of J558L myeloma tu-
mors, which naturally express high levels of
B7-H1, was significantly reduced in PD-1
deficient mice, as well as in normal mice
following B7-H1 blockade [44]. In other
models, it was shown that B7-H1 blockade
reversed the suppressive phenotypes of both
myeloid  and  plasmacytoid  DCs  derived
from both human and murine tumor envi-
ronments [45,46]. It is interesting to note
that in the majority of these models, effector
CD8+ T cells were required for the anti-
tumor effect. As such, it was shown that
adoptive transfer of tumor draining lympho-
cytes to treat established murine tumors was
also enhanced by B7-H1 blockade [47]. 
Additional Modes of B7-H1 Action
Interestingly, B7-H1 expression on can-
cer cells may induce intrinsic resistance to
T cell attack upon binding by PD-1, result-
ing in a so-called molecular shield against
CD8+ T cell mediated cytotoxicity [31]. B7-
H1 can deliver an anti-apoptotic signal into
cancer  cells  that  prevents  Fas  -mediated
apoptosis [31]. In this model, it was shown
that cancer cells transfected with the full
length B7-H1 molecule conferred cancer
cell resistance to lysis by antigen-specific
CD8+ T cells, while cancer cells transfected
with B7-H1 lacking the cytoplasmic tail lost
resistance to CD8+ T cell mediated lysis.
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shield on cancer cells to prevent killing by
effector immune cells but could possibly
also provide resistance to other types of anti-
cancer agents through cell intrinsic mecha-
nisms.  Regardless  of  the  mechanisms
governing B7-H1/PD-1 bi-directional inter-
actions, blockade by either PD-1 or B7-H1
mAbs should effectively prevent both sup-
pressive signals to T cells through PD-1 and
anti-apoptotic  signals  through  B7-H1  on
cancer cells.  
It has been shown that B7-H1 also can
bind to B7-1 on activated T cells, thus con-
ferring B7-H1 with additional roles in mod-
ulation of immune function [32,33]. In a
series of in vitro studies, one group showed
that B7-H1 specifically interacts with B7-1
to inhibit T cell activation and proliferation
[32,33]. Interestingly, either B7-1 or B7-H1
expressed on the T cells has an inhibitory ef-
fect  after  receiving  a  signal  from  plate-
bound (cross-linking) B7-H1Ig or B7-1Ig
protein, respectively [32,33]. We have re-
cently demonstrated that B7-H1 delivers an
inhibitory signal through B7-1 on T cells to
induce  T  cell  anergy  in  a  mouse  model
[32,33]. Specific mAb blockade of the B7-
H1/B7-1 interaction was capable of both
preventing tolerance induction of naive T
cells and restoring antigen responsiveness to
previously anergized cells [32,33]. Thus, the
role of B7-H1 in T cell function is multi-di-
mensional.  
The effects of B7-H1/B7-1 interactions
in the suppression of tumor immunity are
not fully understood and will need to be de-
fined by future experiments. However, the
discovery of the B7-H1/B7-1 interactions
has  important  implications  for  designing
mAb immunotherapy strategies. The data
suggest that PD-1 mAb blockade on T cells
alone may not be sufficient to eliminate all
the suppressive effects of B7-H1, while B7-
H1 mAbs with the capacity to block B7-H1
binding to both PD-1 and B7-1 may be ef-
fective in enhancing tumor immunity. How-
ever, B7-H1 mAbs will not block B7-DC
interactions with PD-1, which is also poten-
tially suppressive for T cell responses, al-
though  the  biological  significance  of
B7-DC/PD-1 interactions remains unclear at
this time [35,36]. The complexity of these
molecular interactions suggests that B7-H1
or PD-1 blockade alone may be insufficient
to completely block inhibitory pathways and
that a combination of both B7-H1and PD-1
blockades may be optimal for cancer im-
munotherapy. 
Clinical Outcomes with mAbs to Block
the B7-H1/PD-1 Pathway
Currently,  antagonist  mAbs  against
both PD-1 and B7-H1 are in various stages
of development for the treatment of cancer,
and recent human trials have shown promis-
ing results in cancer patients with advanced,
treatment-refractory disease.  
The first of the agents blocking the B7-
H1/PD-1 pathway to enter phase I clinical
trials was MDX-1106 (BMS-936558/ONO-
4538), a fully human IgG4 anti-PD-1 mAb
developed by Bristol-Myers Squibb [48]. In
this multi-center trial, small cohorts of pa-
tients were administered a single dose of
0.3, 1.0, 3.0, or 10 mg/kg. Limited re-treat-
ment was allowed for patients with stable
disease or with tumor regression suggestive
of clinical benefit. Re-treatment was given
as two doses spaced 4 weeks apart at inter-
vals of 3 months, for up to six doses of
MDX-1106. The study included 39 patients
with advanced metastatic melanoma, non-
small-cell lung cancer, renal cell carcinoma,
castration-resistant prostate cancer, and col-
orectal cancer. Because anti-PD-1 and other
immunotherapies release a brake on the im-
mune  system,  particular  concerns  were
raised about potential autoimmune adverse
events. These concerns came from clinical
experience with anti-CTLA-4 mAbs (ipili-
mumab, Bristol-Myers Squibb; and treme-
limumab, Pfizer), which induce moderate to
severe  autoimmune-type  side  effects  in-
cluding dermatitis, enterocolitis, hepatitis,
endocrinopathies (including hypophysitis,
thyroiditis,  and  adrenalitis),  arthritis,
uveitis, nephritis, and aseptic meningitis in
up to 30 percent of patients [49,50]. In con-
trast to the anti-CTLA-4 experience, initial
trial results for anti-PD-1 showed that it was
safe, well-tolerated, and induced a low rate
416 Flies et al.: B7-H1 and PD-1 mAb cancer immunotherapyof autoimmune-type side effects [51]. Only
one patient in the initial phase I MDX-1106
trial developed inflammatory colitis, which
was treated with steroids and anti-TNF ther-
apy. 
Phase I studies are typically performed
to assess the safety, toxicity, and pharmaco-
dynamics of a therapy and are generally not
designed to determine clinical activity. Nev-
ertheless, antitumor activity was evident in
the initial MDX-1106 trial. Two patients
(melanoma, non-small cell lung cancer) ex-
perienced regression in several metastatic le-
sions with progression at other sites (“mixed
response”),  two  patients  (melanoma  and
renal cancer) had substantial regression at all
sites (“partial response”), and one patient
with  metastatic  colorectal  cancer  experi-
enced a total remission with disappearance
of all lesions (“complete response”). These
responses  to  MDX-1106  proved  to  be
durable, persisting up to 21+ months post-
treatment [48].
A larger on-going phase I trial was ini-
tiated to determine the safety and maximum
tolerated dose (MTD) of MDX-1106 ad-
ministered IV twice weekly at doses of 1, 3,
and 10 mg/kg. An MTD was not reached,
and subsequently, expanded cohorts of up to
16 patients were accrued at all three dose
levels for patients with metastatic melanoma
and at the 10 mg/kg dose level for patients
with metastatic renal cancer, non-small cell
lung cancer, colon cancer, and castrate-re-
sistant prostate cancer. At the time of initial
analysis, 106 patients who had progressed
on  standard  therapies  had  been  enrolled
[52]. An additional update in January 2011
presented data on 126 patients [53]. Similar
to the initial single dose trial, treatment with
anti-PD-1 was generally well-tolerated. One
treatment-related death due to grade 4 pneu-
monitis and sepsis was reported; other ad-
verse  events  occurring  at  low  frequency
included liver function test elevations, en-
docrinopathies, and fatigue. This study also
found evidence of substantial antitumor ac-
tivity and durable responses in patients with
advanced  disease.  Among  patients  with
metastatic melanoma, 15 of 46 patients ex-
perienced at least a partial response, for an
overall response rate of 32.6 percent [54]. In
metastatic renal cancer, as of January 2011,
seven of 19 (37 percent) patients treated in
both MDX-1106 trials had achieved a par-
tial or complete response. Many of the re-
sponses to MDX-1106 have been durable,
and activity was also observed in patients
with non-small cell lung cancer. An addi-
tional phase I combination study sponsored
by the National Cancer Institute (NCI) of
MDX-1106  with  ipilimumab  for  unre-
sectable malignant melanoma has also been
initiated. Overall, these trial results are re-
markable and provide compelling proof of
concept that inhibition of the B7-H1/PD-1
coinhibitory pathway can produce meaning-
ful anti-cancer activity in patients with mul-
tiple types of advanced cancer.  
Another PD-1 mAb undergoing clinical
evaluation is CT-011, a humanized IgG1
mAb  specific  for  PD-1  developed  by
CureTech Ltd. [55]. A phase I study of 17
patients with advanced hematologic malig-
nancies (including acute myeloid leukemia,
non-Hodgkin  lymphoma,  Hodgkin  lym-
phoma,  and  multiple  myeloma)  assessed
treatment with one dose of 0.2, 0.6, 1.5, 3.0
or 6.0 mg/kg of CT-011. The agent was well-
tolerated,  and  six  patients  (33  percent)
showed clinical activity from the treatment,
including a lymphoma patient experiencing
a complete remission lasting 68+ weeks. Ad-
ditional combination studies of CT-011 with
gemcitabine (pancreatic cancer), p53 genetic
vaccine (advanced solid cancers), and ritux-
imab (lymphoma) have been initiated.
Fully  humanized  anti-B7-H1  mAb
(MDX-1105) developed by Bristol-Myers
Squibb is currently in phase I trials for ad-
vanced melanoma, non-small cell lung car-
cinoma, renal cell carcinoma, and ovarian
cancer. Results have not been presented to
date. 
Enhancing B7-H1 and PD-1 mAb 
Immunotherapy 
The PD-1/B7-H1 molecular pathway is
a negative cosignaling pathway that func-
tions as a cellular checkpoint to suppress on-
going inflammatory and immune responses.
Therefore,  simply  blocking  this  pathway
417 Flies et al.: B7-H1 and PD-1 mAb cancer immunotherapydoes not stimulate a de novo immune re-
sponse. In other words, blockade of this in-
hibitory pathway lifts the tollbooth gate (i.e.,
access to cancer cells) and may release the
brake on the vehicle (i.e., exhausted effec-
tor CD8+ T cells), but it will not accelerate
the car through the gate. Pressure on the gas
pedal via stimulation such as enhanced TCR
signaling and/or costimulatory signaling is
also required. Therefore, a combined ap-
proach to modulate stimulatory pathways
should  significantly  improve  mAb  im-
munotherapeutic outcomes [35,36].
CD137 (4-1BB) is a costimulatory mol-
ecule found on T cells that promotes cellular
survival and proliferation [35,36]. Several
murine transplantable tumor models have
now demonstrated that B7-H1/PD-1 path-
way blockade in combination with agonist
anti-CD137 (4-1BB) mAbs induces signifi-
cantly  enhanced  tumor  regression  when
compared to either mAb treatment as a sin-
gle modality [35,36]. Additionally, a num-
ber  of  other  agonist  mAbs  against
costimulatory  molecules,  such  as  OX40,
CD40, GITR, CD28, and ICOS, may poten-
tially synergize with PD-1/B7-H1 blockade
[56,57]. 
An additional strategy for combination
mAb  immunotherapy  might  be  termed
“multiple brake release therapy” (MBRT),
in which several inhibitory molecules are si-
multaneously targeted for mAb blockade.
For example, several studies have investi-
gated PD-1 blockade in combination with
blockade of CTLA-4, Tim-3 or Lag-3, all of
which are inhibitory CSSMs [58-62]. How-
ever, results using MBRT strategy in animal
models are less dramatic overall than in
combination therapy with costimulatory ag-
onists,  as  the  vehicle  will  not  proceed
through the raised tollgate without (stimula-
tory) fuel for acceleration. Nevertheless, as
demonstrated by the anti-PD-1 clinical data,
in a significant subset of humans, extensive
tumor regression can be achieved by block-
ade of only coinhibitory signals. Therefore,
MBRT may prove to be more effective in
patients  than  in  animal  models.  Conse-
quently, it is possible that a significant num-
ber of patients will respond to blockade of a
single or multiple coinhibitory signals, while
another subset will require both agonist and
antagonist mAb cocktails for the best re-
sults. 
ConCluSIonS AnD outlook
Monoclonal  antibody  immunothera-
peutic abrogation of the PD-1/B7-H1 path-
way  can  profoundly  reverse  immune
inhibition and permit T cell effector function
against a broad range of cancers. Questions
remain, however, about the mechanisms of
action of this molecular axis. Still unclear is
the true nature of how T cell exhaustion and
deletion occurs and the precise role of PD-1
in the differentiation of this CD8+ T cell
subset. The role of PD-1 on CD4+ T cells
also remains largely undefined. Questions
remain about the effects of PD-1 blockade
versus  B7-H1  blockade  in  clinical  im-
munotherapy due to each molecule’s spe-
cific  expression  pattern  and  function.
Moreover, because B7-DC and B7-1 play a
significant role in this cosignaling axis and
because secondary receptors for B7-H1 and
B7-DC have yet to be identified, we are only
just beginning to understand the complex in-
terplay of this system. Nevertheless, it is
clear that this molecular pathway plays an
important role in normal immune modula-
tion and that cancers evade immune activa-
tion and anti-tumor immune function by
preferentially  engaging  this  cosignaling
axis.
Additionally, evidence in murine mod-
els suggests that immunotherapy targeting
the  PD-1/B7-H1  inhibitory  pathways  in
combination with agonist mAbs targeting
stimulatory pathways will result in greatly
enhanced  anti-tumor  immune  activation.
Therefore, as more mAbs move into clinical
trials, it is important to keep in mind that
even though some immunotherapies may
have  lackluster  performance  as  single
agents, more striking effect may be found in
combinatorial therapies.  
The human body is in a constant battle
for survival against myriad external and in-
ternal threats. In the battle against cancer, the
normally “good genes” of the B7-H1/PD-1
418 Flies et al.: B7-H1 and PD-1 mAb cancer immunotherapymolecular axis are manipulated by cancer to
its own advantage, much to the detriment of
the patient. Targeting this subverted pathway
using mAb immunotherapy will allow us to
reverse the malignant outcome promoted by
good genes gone bad in cancer microenvi-
ronments, while maintaining normal immune
function in healthy environments. Anti-B7-
H1/PD-1  mAb  immunotherapies  demon-
strate  significant  progress  in  the  war  on
cancer and should soon become a powerful
addition to the oncologist’s toolbox. 
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